M&A Deal Summary |
|
|---|---|
| Date | 2023-09-12 |
| Target | Vertical Bio |
| Sector | Life Science |
| Buyer(s) | Pierre Fabre S.A. |
| Deal Type | Add-on Acquisition |
SEARCH BY
The Pierre Fabre Group, the second largest independent laboratory in France made Research and Development its core business and the key to its future. Pierre Fabre invests 25% of its annual sales to R&D, in five major therapeutic areas in terms of public health: oncology (the priority R&D area of Pierre Fabre Médicament, with 50% of all R&D expenses), central nervous system, cardiology, internal medicine/urology, dermatology.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-23 |
Igenica Biotherapeutics - Immunotherapies Assets
Burlingame, California, United States Igenica Biotherapeutics, Inc. - Immunotherapies Assets targets immune checkpoints that may reverse the resistance to existing immuno therapies. |
Buy | - |
